The Role of Coenzyme Q10 Supplementation as a Potential Adjunct in the Treatment of Autoimmune Diseases
DOI:
https://doi.org/10.12775/QS.2025.42.61118Keywords
autoimmune diseases, Coenzyme Q10, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Fibromyalgia, Rheumatoid Arthritis, Multiple Sclerosis, Type I Diabetes, Graves’ Disease, Ulcerative Colitis, PsoriasisAbstract
Autoimmune diseases are a heterogeneous group of afflictions whose etiopathogenesis is still incompletely understood. There is a great need to search for new treatment methods because of the difficulty of treatment, the numerous side effects of pharmacotherapy and the life-threatening complications associated with these diseases. The discovered role of mitochondrial dysfunction in the pathogenesis of these conditions and the associated oxidative stress, but also the contribution of coenzyme Q10 to normal mitochondrial function, provided the impetus for research into the use of coenzyme Q10 supplementation as an adjunctive therapy for autoimmune diseases. This review article summarises the role of coenzyme Q10 supplementation in the regulation of impaired processes involved in the pathogenesis of autoimmune diseases and focuses on the potential benefits of coenzyme Q10 supplementation for patients with autoimmune diseases.
References
1. Ernster L., Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta. 1995;1271:195–204. doi: 10.1016/0925-4439(95)00028-3.
2. D. A. Groneberg, B. Kindermann, M. Althammer, M. Klapper, J. Vormann, G. P. Littarru and F. Doring: Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells. Int J Biochem Cell Biol 37(6), 1208-18 (2005)
3. C. M. Quinzii, S. DiMauro and M. Hirano: Human coenzyme Q10 deficiency. Neurochem Res 32(4-5), 723-7 (2007)
4. C. M. Quinzii and M. Hirano: Primary and secondary CoQ(10) deficiencies in humans. Biofactors 37(5), 361-5 (2011)
5. R. S. Sohal and M. J. Forster: Coenzyme Q, oxidative stress and aging. Mitochondrion 7 Suppl, S103-11 (2007)
6. Garrido-Maraver J, Cordero MD, Oropesa-Avila M, Vega AF, de la Mata M, Pavon AD, Alcocer-Gomez E, Calero CP, Paz MV, Alanis M, de Lavera I, Cotan D, Sanchez-Alcazar JA. Clinical applications of coenzyme Q10. Front Biosci (Landmark Ed). 2014 Jan 1;19(4):619-33. doi: 10.2741/4231. PMID: 24389208
7. Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023 Aug;19(8):509-524. doi: 10.1038/s41581-023-00720-1. Epub 2023 May 10. PMID: 37165096; PMCID: PMC10171171.
8. Samuels H, Malov M, Saha Detroja T, Ben Zaken K, Bloch N, Gal-Tanamy M, Avni O, Polis B, Samson AO. Autoimmune Disease Classification Based on PubMed Text Mining. J Clin Med. 2022 Jul 26;11(15):4345. doi: 10.3390/jcm11154345. PMID: 35893435; PMCID: PMC9369164.
9. Ruiz R, Kirk AD. Long-Term Toxicity of Immunosuppressive Therapy. Transplantation of the Liver. 2015:1354–63. doi: 10.1016/B978-1-4557-0268-8.00097-X. Epub 2015 Apr 3. PMCID: PMC7152453.
10. van der Burgh R, Boes M. Mitochondria in autoinflammation: cause, mediator or bystander? Trends Endocrinol Metab. 2015 May;26(5):263-71. doi: 10.1016/j.tem.2015.03.004. Epub 2015 Apr 4. PMID: 25850613.
11. Barrera MJ, Aguilera S, Castro I, Carvajal P, Jara D, Molina C, González S, González MJ. Dysfunctional mitochondria as critical players in the inflammation of autoimmune diseases: Potential role in Sjögren's syndrome. Autoimmun Rev. 2021 Aug;20(8):102867. doi: 10.1016/j.autrev.2021.102867. Epub 2021 Jun 9. PMID: 34118452.
12. Al-Azab M, Qaed E, Ouyang X, Elkhider A, Walana W, Li H, Li W, Tang Y, Adlat S, Wei J, Wang B, Li X. TL1A/TNFR2-mediated mitochondrial dysfunction of fibroblast-like synoviocytes increases inflammatory response in patients with rheumatoid arthritis via reactive oxygen species generation. FEBS J. 2020 Jul;287(14):3088-3104. doi: 10.1111/febs.15181. Epub 2020 Jan 17. PMID: 31953914.
13. Hidaka T, Fujii K, Funahashi I, Fukutomi N, Hosoe K. Safety assessment of coenzyme Q10 (CoQ10). Biofactors. 2008;32(1-4):199-208. doi: 10.1002/biof.5520320124. PMID: 19096117
14. Arreola-Diaz R, Majluf-Cruz A, Sanchez-Torres LE, Hernandez-Juarez J. The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221088576. doi: 10.1177/10760296221088576. PMID: 35317658; PMCID: PMC8950029.
15. Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun. 2014 Feb-Mar;48-49:20-5. doi: 10.1016/j.jaut.2014.01.006. Epub 2014 Jan 24. PMID: 24461539.
16. Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, Segui P, Collantes-Estevez E, Barbarroja N, Khraiwesh H, Gonzalez-Reyes JA, Villalba JM, Velasco F, Cuadrado MJ, Lopez-Pedrera C. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. Blood. 2012 Jun 14;119(24):5859-70. doi: 10.1182/blood-2011-12-400986. Epub 2012 Apr 23. PMID: 22529290.
17. Savino Sciascia, Chary Lopez-Pedrera, Irene Cecchi, Clara Pecoraro, Dario Roccatello, Maria Josè Cuadrado, Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome, Rheumatology, Volume 55, Issue 10, October 2016, Pages 1726–1735, https://doi.org/10.1093/rheumatology/kev445
18. Pérez-Sánchez C, Aguirre MÁ, Ruiz-Limón P, Ábalos-Aguilera MC, Jiménez-Gómez Y, Arias-de la Rosa I, Rodriguez-Ariza A, Fernández-Del Río L, González-Reyes JA, Segui P, Collantes-Estévez E, Barbarroja N, Velasco F, Sciascia S, Cecchi I, Cuadrado MJ, Villalba JM, López-Pedrera C. Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial. Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1923-1932. doi: 10.1161/ATVBAHA.117.309225. Epub 2017 Jul 6. PMID: 28684614.
19. Smolen, J.S.; Aletaha, D.; McInnes, I.B. Rheumatoid arthritis. Lancet Lond. Engl. 2016, 388, 2023–2038.
20. Petrelli F, Mariani FM, Alunno A, Puxeddu I. Pathogenesis of rheumatoid arthritis: one year in review 2022. Clin Exp Rheumatol. 2022 Mar;40(3):475-482. doi: 10.55563/clinexprheumatol/l9lyen. Epub 2022 Mar 10. PMID: 35333708.
21. López-Armada MJ, Fernández-Rodríguez JA, Blanco FJ. Mitochondrial Dysfunction and Oxidative Stress in Rheumatoid Arthritis. Antioxidants (Basel). 2022 Jun 12;11(6):1151. doi: 10.3390/antiox11061151. PMID: 35740048; PMCID: PMC9220001.
22. Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid Arthritis: A Brief Overview of the Treatment. Med Princ Pract. 2018;27(6):501-507. doi: 10.1159/000493390. Epub 2018 Sep 2. PMID: 30173215; PMCID: PMC6422329.
23. Jhun, J.; Lee, S.H.; Byun, J.K.; Jeong, J.H.; Kim, E.K.; Lee, J.; Jung, Y.O.; Shin, D.; Park, S.H.; Cho, M.L. Coenzyme Q10 suppresses Th17 cells and osteoclast differentiation and ameliorates experimental autoimmune arthritis mice. Immunol. Lett. 2015, 166, 92–102
24. Bauerova, K.; Paulovicova, E.; Mihalova, D.; Drafi, F.; Strosova, M.; Mascia, C.; Biasi, F.; Rovensky, J.; Kucharska, J.; Gvozdjakova, A.; et al. Combined methotrexate and coenzyme Q10 therapy in adjuvant-induced arthritis evaluated using parameters of inflammation and oxidative stress. Acta Biochim. Pol. 2010, 57, 347–354.
25. Abdollahzad, H.; Aghdashi, M.A.; Asghari Jafarabadi, M.; Alipour, B. Effects of Coenzyme Q10 Supplementation on Inflammatory Cytokines (TNF-α, IL-6) and Oxidative Stress in Rheumatoid Arthritis Patients: A Randomized Controlled Trial. Arch. Med. Res. 2015, 46, 527–533.
26. Nachvak SM, Alipour B, Mahdavi AM, Aghdashi MA, Abdollahzad H, Pasdar Y, Samadi M, Mostafai R. Effects of coenzyme Q10 supplementation on matrix metalloproteinases and DAS-28 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial. Clin Rheumatol. 2019 Dec;38(12):3367-3374. doi: 10.1007/s10067-019-04723-x. Epub 2019 Aug 7. PMID: 31392559.
27. Rees, F.; Doherty, M.; Grainge, M.J.; Lanyon, P.; Zhang, W. The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. Rheumatology 2017, 56, 1945–1961.
28. Accapezzato D, Caccavale R, Paroli MP, Gioia C, Nguyen BL, Spadea L, Paroli M. Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. Int J Mol Sci. 2023 Mar 31;24(7):6578. doi: 10.3390/ijms24076578. PMID: 37047548; PMCID: PMC10095030.
29. Touma Z, Gladman DD. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci Med. 2017 Dec 17;4(1):e000239. doi: 10.1136/lupus-2017-000239. PMID: 29344386; PMCID: PMC5761306.
30. Zhao L, Hu X, Xiao F, Zhang X, Zhao L, Wang M. Mitochondrial impairment and repair in the pathogenesis of systemic lupus erythematosus. Front Immunol. 2022 Jul 25;13:929520. doi: 10.3389/fimmu.2022.929520. PMID: 35958572; PMCID: PMC9358979.
31. Blanco LP, Pedersen HL, Wang X, Lightfoot YL, Seto N, Carmona-Rivera C, Yu ZX, Hoffmann V, Yuen PST, Kaplan MJ. Improved Mitochondrial Metabolism and Reduced Inflammation Following Attenuation of Murine Lupus With Coenzyme Q10 Analog Idebenone. Arthritis Rheumatol. 2020 Mar;72(3):454-464. doi: 10.1002/art.41128. Epub 2020 Jan 27. PMID: 31566908; PMCID: PMC7050361.
32. Marques AP, Santo ASDE, Berssaneti AA, Matsutani LA, Yuan SLK. Prevalence of fibromyalgia: literature review update. Rev Bras Reumatol Engl Ed. 2017 Jul-Aug;57(4):356-363. English, Portuguese. doi: 10.1016/j.rbre.2017.01.005. Epub 2017 Feb 8. PMID: 28743363.
33. Siracusa R, Paola RD, Cuzzocrea S, Impellizzeri D. Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update. Int J Mol Sci. 2021 Apr 9;22(8):3891. doi: 10.3390/ijms22083891. PMID: 33918736; PMCID: PMC8068842.
34. Cordero MD, De Miguel M, Moreno Fernández AM, Carmona López IM, Garrido Maraver J, Cotán D, Gómez Izquierdo L, Bonal P, Campa F, Bullon P, Navas P, Sánchez Alcázar JA. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther. 2010;12(1):R17. doi: 10.1186/ar2918. Epub 2010 Jan 28. PMID: 20109177; PMCID: PMC2875645.
35. Cordero MD, Alcocer-Gómez E, de Miguel M, Culic O, Carrión AM, Alvarez-Suarez JM, Bullón P, Battino M, Fernández-Rodríguez A, Sánchez-Alcazar JA. Can coenzyme q10 improve clinical and molecular parameters in fibromyalgia? Antioxid Redox Signal. 2013 Oct 20;19(12):1356-61. doi: 10.1089/ars.2013.5260. Epub 2013 Apr 6. PMID: 23458405.
36. Cordero MD, Cano-García FJ, Alcocer-Gómez E, De Miguel M, Sánchez-Alcázar JA. Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q₁₀ effect on clinical improvement. PLoS One. 2012;7(4):e35677. doi: 10.1371/journal.pone.0035677. Epub 2012 Apr 19. PMID: 22532869; PMCID: PMC3330812.
37. Tafti D, Ehsan M, Xixis KL. Multiple Sclerosis. 2024 Mar 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 29763024.
38. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Angood Napier C, Rijke N, Baneke P. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26(14):1816-1821. doi: 10.1177/1352458520970841. Epub 2020 Nov 11. PMID: 33174475; PMCID: PMC7720355.
39. Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024 Feb 23;103(8):e37297. doi: 10.1097/MD.0000000000037297. PMID: 38394496; PMCID: PMC10883637.
40. Hart FM, Bainbridge J. Current and emerging treatment of multiple sclerosis. Am J Manag Care. 2016 Jun;22(6 Suppl):s159-70. PMID: 27356025.
41. Racke MK. Challenges in developing new multiple sclerosis therapies. Ther Adv Neurol Disord. 2008 Sep;1(2):1-3. doi: 10.1177/1756285608095831. PMID: 21180565; PMCID: PMC3002543.
42. López-Muguruza E, Matute C. Alterations of Oligodendrocyte and Myelin Energy Metabolism in Multiple Sclerosis. Int J Mol Sci. 2023 Aug 18;24(16):12912. doi: 10.3390/ijms241612912. PMID: 37629092; PMCID: PMC10454078.
43. Gironi M, Borgiani B, Mariani E, Cursano C, Mendozzi L, Cavarretta R, Saresella M, Clerici M, Comi G, Rovaris M, Furlan R. Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. J Immunol Res. 2014;2014:961863. doi: 10.1155/2014/961863. Epub 2014 Mar 26. PMID: 24741637; PMCID: PMC3984797.
44. Soleimani M, Jameie SB, Barati M, Mehdizadeh M, Kerdari M. Effects of coenzyme Q10 on the ratio of TH1/TH2 in experimental autoimmune encephalomyelitis model of multiple sclerosis in C57BL/6. Iran Biomed J. 2014;18(4):203-11. doi: 10.6091/ibj.13362.2014. PMID: 25326018; PMCID: PMC4225059.
45. Moccia M, Capacchione A, Lanzillo R, Carbone F, Micillo T, Perna F, De Rosa A, Carotenuto A, Albero R, Matarese G, Palladino R, Brescia Morra V. Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis. Ther Adv Neurol Disord. 2019 Feb 18;12:1756286418819074. doi: 10.1177/1756286418819074. PMID: 30815035; PMCID: PMC6381428.
46. Sanoobar M, Eghtesadi S, Azimi A, Khalili M, Khodadadi B, Jazayeri S, Gohari MR, Aryaeian N. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci. 2015 May;18(4):169-76. doi: 10.1179/1476830513Y.0000000106. Epub 2014 Jan 10. PMID: 24621064.
47. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Apr;138:271-281. doi: 10.1016/j.diabres.2018.02.023. Epub 2018 Feb 26. PMID: 29496507.
48. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018 Jun 16;391(10138):2449-2462. doi: 10.1016/S0140-6736(18)31320-5. PMID: 29916386; PMCID: PMC6661119.
49. Paschou SA, Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. On type 1 diabetes mellitus pathogenesis. Endocr Connect. 2018 Jan;7(1):R38-R46. doi: 10.1530/EC-17-0347. Epub 2017 Nov 30. PMID: 29191919; PMCID: PMC5776665.
50. Yaribeygi H, Sathyapalan T, Atkin SL, Sahebkar A. Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus. Oxid Med Cell Longev. 2020 Mar 9;2020:8609213. doi: 10.1155/2020/8609213. PMID: 32215179; PMCID: PMC7085395.
51. Boscari F, Avogaro A. Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives. Rev Endocr Metab Disord. 2021 Jun;22(2):217-240. doi: 10.1007/s11154-021-09635-3. Epub 2021 Mar 23. PMID: 33755854; PMCID: PMC7985920.
52. Sourris KC, Harcourt BE, Tang PH, Morley AL, Huynh K, Penfold SA, Coughlan MT, Cooper ME, Nguyen TV, Ritchie RH, Forbes JM. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med. 2012 Feb 1;52(3):716-723. doi: 10.1016/j.freeradbiomed.2011.11.017. Epub 2011 Nov 21. PMID: 22172526.
53. Brauner H, Lüthje P, Grünler J, Ekberg NR, Dallner G, Brismar K, Brauner A. Markers of innate immune activity in patients with type 1 and type 2 diabetes mellitus and the effect of the anti-oxidant coenzyme Q10 on inflammatory activity. Clin Exp Immunol. 2014 Aug;177(2):478-82. doi: 10.1111/cei.12316. PMID: 24593795; PMCID: PMC4226598.
54. Montano SJ, Grünler J, Nair D, Tekle M, Fernandes AP, Hua X, Holmgren A, Brismar K, Ungerstedt JS. Glutaredoxin mediated redox effects of coenzyme Q10 treatment in type 1 and type 2 diabetes patients. BBA Clin. 2015 Jun 10;4:14-20. doi: 10.1016/j.bbacli.2015.06.001. PMID: 26966682; PMCID: PMC4737908.
55. Pokhrel B, Bhusal K. Graves Disease. 2023 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 28846288.
56. Vejrazkova D, Vcelak J, Vaclavikova E, Vankova M, Zajickova K, Duskova M, Vrbikova J, Bendlova B. Genetic predictors of the development and recurrence of Graves' disease. Physiol Res. 2018 Nov 28;67(Suppl 3):S431-S439. doi: 10.33549/physiolres.934018. PMID: 30484670.
57. Bogusławska J, Godlewska M, Gajda E, Piekiełko-Witkowska A. Cellular and molecular basis of thyroid autoimmunity. Eur Thyroid J. 2022 Jan 1;11(1):e210024. doi: 10.1530/ETJ-21-0024. PMID: 34981746; PMCID: PMC9142813.
58. Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 2014 Apr;94(2):355-82. doi: 10.1152/physrev.00030.2013. PMID: 24692351; PMCID: PMC4044302.
59. Mancini A, Di Segni C, Raimondo S, Olivieri G, Silvestrini A, Meucci E, Currò D. Thyroid Hormones, Oxidative Stress, and Inflammation. Mediators Inflamm. 2016;2016:6757154. doi: 10.1155/2016/6757154. Epub 2016 Mar 8. PMID: 27051079; PMCID: PMC4802023.
60. Kahaly GJ. Management of Graves Thyroidal and Extrathyroidal Disease: An Update. J Clin Endocrinol Metab. 2020 Dec 1;105(12):3704–20. doi: 10.1210/clinem/dgaa646. PMID: 32929476; PMCID: PMC7543578.
61. Suzuki H, Naitoh T, Kuniyoshi S, Banba N, Kuroda H, Suzuki Y, Hiraiwa M, Yamazaki N, Ishikawa M, Hashigami Y, et al. Cardiac performance and coenzyme Q10 in thyroid disorders. Endocrinol Jpn. 1984 Dec;31(6):755-61. doi: 10.1507/endocrj1954.31.755. PMID: 6532793.
62. Moncayo, R.; Moncayo, H. Practical Guidelines for Diagnosing and Treating Thyroid Disease Based on the WOMED Metabolic Model of Disease Focusing on Glycolysis and Coenzyme Q10 Deficiency-A Clinical Alternative to the 2021 Retired Clinical Practice Guidelines of the Endocrine Society. Diagnostics 2022, 12, 107.
63. Lynch WD, Hsu R. Ulcerative Colitis. 2023 Jun 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 29083748.
64. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16. Erratum in: Lancet. 2020 Oct 3;396(10256):e56. doi: 10.1016/S0140-6736(20)32028-6. PMID: 29050646.
65. Porter RJ, Kalla R, Ho GT. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Res. 2020 Apr 24;9:F1000 Faculty Rev-294. doi: 10.12688/f1000research.20805.1. PMID: 32399194; PMCID: PMC7194476.
66. Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond). 2021 Mar;21(2):135-139. doi: 10.7861/clinmed.2021-0080. PMID: 33762374; PMCID: PMC8002778.
67. Fukuda T, Naganuma M, Kanai T. Current new challenges in the management of ulcerative colitis. Intest Res. 2019 Jan;17(1):36-44. doi: 10.5217/ir.2018.00126. Epub 2019 Jan 25. PMID: 30678445; PMCID: PMC6361009.
68. Ho GT, Aird RE, Liu B, Boyapati RK, Kennedy NA, Dorward DA, Noble CL, Shimizu T, Carter RN, Chew ETS, Morton NM, Rossi AG, Sartor RB, Iredale JP, Satsangi J. MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. Mucosal Immunol. 2018 Jan;11(1):120-130. doi: 10.1038/mi.2017.31. Epub 2017 Apr 12. PMID: 28401939; PMCID: PMC5510721.
69. Shastri, S.; Shinde, T.; Sohal, S.S.; Gueven, N.; Eri, R. Idebenone Protects against Acute Murine Colitis via Antioxidant and Anti-Inflammatory Mechanisms. Int. J. Mol. Sci. 2020, 21, 484.
70. Ewees MG, Messiha BA, Abo-Saif AA, Abd El-Latif HA. Is Coenzyme Q10 Effective in Protection against Ulcerative Colitis? An Experimental Study in Rats. Biol Pharm Bull. 2016;39(7):1159-66. doi: 10.1248/bpb.b16-00124. PMID: 27374290.
71. Farsi F, Ebrahimi-Daryani N, Barati M, Janani L, Karimi MY, Akbari A, Irandoost P, Mesri Alamdari N, Agah S, Vafa M. Effects of coenzyme Q10 on health-related quality of life, clinical disease activity and blood pressure in patients with mild to moderate ulcerative colitis: a randomized clinical trial. Med J Islam Repub Iran. 2021 Jan 6;35:3. doi: 10.47176/mjiri.35.3. PMID: 33996654; PMCID: PMC8111632.
72. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM, Global Psoriasis A (2020) National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 369:m1590-m
73. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017 Mar;76(3):377-390. doi: 10.1016/j.jaad.2016.07.064. PMID: 28212759; PMCID: PMC5731650.
74. Petit RG, Cano A, Ortiz A, Espina M, Prat J, Muñoz M, Severino P, Souto EB, García ML, Pujol M, Sánchez-López E. Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. Int J Mol Sci. 2021 May 7;22(9):4983. doi: 10.3390/ijms22094983. PMID: 34067151; PMCID: PMC8125586.
75. Ahmad Jamil H, Abdul Karim N. Unraveling Mitochondrial Reactive Oxygen Species Involvement in Psoriasis: The Promise of Antioxidant Therapies. Antioxidants (Basel). 2024 Oct 11;13(10):1222. doi: 10.3390/antiox13101222. PMID: 39456475; PMCID: PMC11505169.
76. Lee HJ, Kim M. Challenges and Future Trends in the Treatment of Psoriasis. Int J Mol Sci. 2023 Aug 28;24(17):13313. doi: 10.3390/ijms241713313. PMID: 37686119; PMCID: PMC10487560.
77. Kharaeva Z, Gostova E, De Luca C, Raskovic D, Korkina L. Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients. Nutrition. 2009 Mar;25(3):295-302. doi: 10.1016/j.nut.2008.08.015. Epub 2008 Nov 28. PMID: 19041224.
78. Al-Oudah GA, Sahib AS, Al-Hattab MK, Al-Ameedee AA. Effect of CoQ10 Administration to Psoriatic Iraqi Patients on Biological Therapy Upon Severity Index (PASI) and Quality of Life Index (DLQI) Before and After Therapy. J Popul Ther Clin Pharmacol. 2022 Jun 16;29(2):e52-e60. doi: 10.47750/jptcp.2022.931. PMID: 35848197.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Martyna Bukała, Karolina Ochyra, Kornelia Pudło, Jowita Frydrych, Gabriela Prucnal, Karolina Ryba, Katarzyna Znamirowska, Klaudia Zacher, Patrycja Walkiewicz, Anna Rakoczy
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 54
Number of citations: 0
